Market Overview

UPDATE: Credit Suisse Reiterates Neutral Rating, Raises PT on Medtronic

Related MDT
Medtronic Micra TPS Meets Global Clinical Trial's Safety and Effectiveness Endpoints
13 Stocks To Watch In The Healthcare Space
Tracking The Hotchkis & Wiley Value Opportunities Fund - Q3 2015 Update (Seeking Alpha)

In a report published Wednesday, Credit Suisse Group reiterated its Neutral rating on Medtronic (NYSE: MDT), and slightly raised its price target from $46.00 to $47.00.

Credit Suisse noted, “We see the last 2 Qs as evidence of MDT's ability to drive an improving top-line through emerging markets execution, recovery in key developed markets & M&A. Given MDT's improving top-line and conservative guidance we believe the company is the best positioned among the large-cap cardio names for near-term share price upside (though we highlight added BMP fallout as a near-term risk). We're raising our price target to $47 from $46 on a lower assumed WACC.”

Medtronic closed on Tuesday at $42.66.

Latest Ratings for MDT

Nov 2015Credit SuisseMaintainsOutperform
Oct 2015Evercore ISI GroupUpgradesHoldBuy
Sep 2015JefferiesMaintainsHold

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Credit Suisse GroupAnalyst Color Price Target Analyst Ratings


Related Articles (MDT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters